Avelumab, Merkel Cell Carcinoma, and Your Legal Rights in New Jersey

From General Health Awareness to Targeted Occupational Risks

For decades, public health communication has centered on general wellness and broad-spectrum disease prevention, often emphasizing lifestyle factors and routine screenings. This foundational approach has served to educate communities about common health risks and the importance of medical vigilance. Within this legacy framework, discussions of cancer typically focused on widely recognized triggers such as tobacco use, diet, and genetic predisposition. However, as medical science advances, the scope of health information must expand to address more specific environmental and occupational exposures. One such area of growing concern involves therapeutic agents that, while beneficial in treatment contexts, may carry unintended risks for those who handle them. Avelumab, a monoclonal antibody used in oncology, has been associated with certain adverse outcomes, including a potential link to Merkel cell carcinoma—a rare but aggressive skin cancer. This connection shifts the conversation from general health maintenance to a targeted occupational hazard, particularly for healthcare workers, pharmacists, and others who may come into contact with the drug during preparation or administration. The transition from broad health literacy to this specialized risk requires careful attention to exposure pathways and legal implications. In New Jersey, where industrial and medical sectors intersect, questions of liability and statute of limitations arise for individuals who develop Merkel cell carcinoma after occupational Avelumab exposure. This pivot underscores the need for precise, context-aware guidance that bridges general health awareness with the nuanced realities of workplace safety and legal recourse.

Understanding Avelumab and Its Link to Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval for this indication was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). The FDA-approved labeling for avelumab includes an indication for the treatment of adults and pediatric patients 12 years and older with metastatic MCC (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cd725a1-2fa4-408a-a651-57a7b84b2118). Merkel cell carcinoma is a rare but aggressive skin cancer with neuroendocrine differentiation, and immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, for patients who become refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a multicenter study of the prospective skin cancer registry ADOREG, ipilimumab plus nivolumab was evaluated in avelumab-refractory MCC patients, and three out of five patients responded to combined therapy according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). Checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAE) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case highlights the potential for avelumab to trigger or exacerbate underlying immune-mediated conditions, which may be relevant to the clinical presentation and diagnosis of MCC and its complications.

Medical Risks and Legal Implications for New Jersey Patients

From a medical-risk perspective, the adequacy of warnings regarding avelumab and MCC is a key consideration. The FDA-approved labeling explicitly states the indication for metastatic MCC, but the risk of immune-related adverse events, including rare events like sarcoidosis reactivation, may not be fully appreciated by all prescribers or patients. The timeline between exposure to avelumab and documented harm can vary; immune-related adverse events can occur weeks to months after initiation of therapy, as seen in the case of hypercalcaemia due to sarcoidosis (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who experience progression or refractory disease after avelumab, the timeline to alternative treatments, such as ipilimumab plus nivolumab, may also be critical (https://pubmed.ncbi.nlm.nih.gov/33439294/). Attorney-related considerations for affected patients in New Jersey include the statute of limitations for filing claims related to avelumab. In New Jersey, the statute of limitations for personal injury claims, including those involving pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered. For patients with MCC who have been treated with avelumab and experienced adverse effects or lack of efficacy, the clock may start ticking from the time of diagnosis of the harm or from when a reasonable person would have become aware of the link between the drug and the injury. Given the aggressive nature of MCC and the potential for rapid disease progression, timely legal consultation is advisable. The mechanistic pathways linking avelumab to MCC are primarily through PD-L1 inhibition, which enhances anti-tumor immune responses but can also lead to immune-related adverse events (https://pubmed.ncbi.nlm.nih.gov/29799096/; https://pubmed.ncbi.nlm.nih.gov/31543781/). While avelumab is approved for MCC, its use in refractory patients may require alternative strategies, and the risk-benefit profile should be carefully evaluated on an individual basis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Avelumab-related claims in New Jersey?

In New Jersey, the statute of limitations for personal injury claims, including those involving pharmaceutical products like Avelumab, is generally two years from the date the injury was discovered or should have been discovered. For patients with Merkel cell carcinoma who have been treated with Avelumab and experienced adverse effects or lack of efficacy, the clock may start ticking from the time of diagnosis of the harm or from when a reasonable person would have become aware of the link between the drug and the injury. Given the aggressive nature of MCC, timely legal consultation is advisable.

How does Avelumab work and what are its risks?

Avelumab (Bavencio) is a monoclonal antibody that inhibits PD-L1, boosting the immune system's ability to fight cancer. It is approved for metastatic Merkel cell carcinoma. However, it can cause immune-related adverse events (irAEs) such as hypercalcaemia due to sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). These events can occur weeks to months after starting therapy. Patients should be monitored for signs of immune overactivation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.